-
NASH Trial
NASH, often a silent liver condition, typically remains undetected until it becomes advanced. It begins with an accumulation of fat in the liver and can progress to significant liver injury. Taking early measures is crucial to curb its severity.
Read more
Criteria & Qualifications: • Participants need to be aged 18 or older.
• Must have a diagnosis of Fatty Liver Disease.
Compensation: Contact us for more information -
NASH Study
NASH is a liver disease with inflammation and damage from fat buildup. If you have NASH, consider participating in our study to help find new treatments.
Read more
Criteria & Qualifications: • Must be 18 years or older.
• Diagnosed with Ulcerative Colitis.
• Is willing to provide medical records.
Compensation: Contact us for more information -
NASH
Coming Soon! NASH is a quiet liver disease that often shows no symptoms until it's severe. It starts with extra liver fat and can lead to serious liver damage. Early action is key to preventing it from getting worse.
Read more
Criteria & Qualifications: • Must be over 18 years old.
• Diagnosed with Fatty Liver Disease.
Compensation: Contact us for more information -
Obesity Study
This clinical trial investigates the effects of a new medication on morbidity and mortality in adults experiencing obesity. The study aims to provide substantial evidence of the drug’s potential clinical benefits for obesity management.
Read more
Criteria & Qualifications: • Males and Females in good general health.
• BMI greater than 27.
Compensation: Up to $800. -
NASH Study
Nonalcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver. NASH, the more severe form, causes swelling and damage to the liver. Currently, there is no existing treatment for NASH.
Read more
Criteria & Qualifications: • Is at least 18 years of age or older.
• Inflammation and liver damage, also known as Nonalcoholic steatohepatitis (NASH).
• Must be weight stable for 6 months.
Compensation: Up to $3,000.
Getting Ready for
First Screening
Learn what to expect at your initial trial screening.
